Trial Profile
RTOG 0436: A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin and Radiation for Patients with Esophageal Cancer who are Treated without Surgery
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jun 2022
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Paclitaxel
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 23 May 2022 Status changed from active, no longer recruiting to completed.
- 14 Feb 2018 Planned End Date changed from 1 Aug 2018 to 1 Apr 2020.
- 30 May 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.